The timing of the exposure during pregnancy made a big difference in the level of risk associated with developing an allergic condition.

MSD unveiled the launch of the Phase III trials of MK-8527 at the International AIDS Society (IAS) 2025 conference.

AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial of the highly selective ASI, baxdrostat.

Amylyx has presented new exploratory analyses from the Phase II PREVENT and Phase IIb trials of avexitide for PBH treatment.

Crinetics Pharmaceuticals has revealed new data from its clinical development programme for Palsonify, an oral treatment for acromegaly.

UK & Ireland, experts provided insights on market trends within the clinical trial industry and advice on engagement strategies.

LEO Pharma has reported outcomes from the 16-week interim analysis of the Phase IIIb ADHAND trial of tralokinumab for hand atopic dermatitis (AD).

The US FDA has approved Purespring Therapeutics’ IND application for PS-002, allowing the company to begin a Phase I/II trial.

A panel at CTO East Coast discussed the regulatory changes impacting oncology trials and how these can be managed.

UroGen Pharma has completed the enrolment of subjects in its Phase III UTOPIA trial, which is evaluating UGN-103 for intravesical solution.

A strategic framework has been devised with nine priority actions to enhance quality, accessibility, innovation and sustainability in trials.

Arrowhead has dosed the first participant in the Phase III YOSEMITE trial of zodasiran, under development for treating HoFH.